


Freire, E.

Kinetic Analysis of the Conformational Stability and  
Aggregation of mAbs Using Calorimetry  
or  
Two New Things To Do With Your Calorimeter

Ernesto Freire  
[ef@jhu.edu](mailto:ef@jhu.edu)

Johns Hopkins University


# mAbs Denature and Aggregate



Partial Denaturation or Complete Denaturation Can Lead to Aggregation


# Strategies to Slow Down Denaturation/Aggregation Freire, E.

- Lower Concentration of Aggregating Species



Solution: Increase  $T_m$  or  $\Delta G$

- Decrease Intrinsic Rate of Aggregation



Solution: Increase Activation Energy  $\Delta H^*$

# Case Study: VRC07-523LS, a Broadly Neutralizing HIV-1 Antibody Currently in Phase 1 Clinical Trials

- VRC07-523LS is a VRC01 class IgG1 neutralizing antibody
- mAb VRC01 binds to CD4 binding site in envelope glycoprotein gp120. It neutralizes ~90% of HIV-1 strains with an IC50 of less than 50 µg/ml
- VRC07 was identified through sequencing antibody-gene transcripts of VRC01 donor B cells
  - Structure-based design was used to further optimize VRC07
  - VRC07-523LS is 5- to 8-fold more potent than VRC01
  - It neutralizes 96% of viruses tested



# Temperature Denaturation of mAbs is an Irreversible Process Freire, E.

DSC Usually Shows Peaks Corresponding to Fab, CH2 and CH3 Domains







Fig 1. (A) DSC curve of the BIIB7 IgG<sub>1</sub>. Above the curves are structures of a full-length human IgG<sub>1</sub> antibody (13). (B) DSC curves representing the four human IgG subclasses.


# Irreversible Denaturation is Kinetically Controlled




The kinetic control of irreversible protein denaturation in DSC was first discussed by Sanchez-Ruiz et al Biochemistry (1988) 27 1648.

# The Rate of Denaturation Increases With Temperature

At  $T_m$  the Rate of Denaturation is  $\sim 1$  minute




# Temperature Denaturation is Kinetically Controlled



The Stability at Lower Temperatures Depends on the Activation Enthalpy  $\Delta H^*$ .

- The Higher  $\Delta H^*$ , the Higher the Stability.
- In Formulation or mAb Selection we want to Increase  $\Delta H^*$  to Maximize Long Term Stability


# The Temperature Dependence of the Rate of Denaturation is Determined by the Activation Energy $\Delta H^*$



The Higher  $\Delta H^*$  the Faster the Decrease of the Rate of Denaturation/Aggregation Upon Lowering the Temperature

# Kinetic Deconvolution of DSC for Irreversible Denaturation

Freire, E.



$\Delta H_i^*$  Can be Determined from Kinetic Deconvolution

# Kinetic Deconvolution of DSC for Irreversible Denaturation Using Exact Equations

$$C_p = \sum \Delta H_i \frac{dF_{d,i}}{dT}$$

$$\frac{dF_{d,i}}{dt} = k_i F_{d,i}$$

$$\frac{dF_{d,i}}{dT} = \frac{k_i F_{d,i}}{\alpha}$$


$$\alpha = \frac{dT}{dt} = \text{scan rate}$$

$$\frac{d \ln F_{d,i}}{dT} = \frac{k_i}{\alpha} = \frac{\exp\left(-\frac{\Delta G_i^*}{RT}\right)}{\alpha}$$


$$k_i = \exp\left(-\frac{\Delta G_i^*}{RT}\right) = \exp\left(-\frac{\Delta H_i^* - T\Delta S_i^*}{RT}\right)$$

$\Delta H_i^*$  Can be Determined from Kinetic Deconvolution


# The Effect of the Activation Enthalpy ( $\Delta H^*$ ) on the Shape of the DSC Curve





## DSC Data and Kinetic Deconvolution as a Function of pH for mAb VRC07





## Kinetic Deconvolution of Cp Function of VRC07 pH 6.8





pH Dependence of  $T_m$  and Activation Enthalpy

# Combination of $T_m$ and Activation Enthalpy Indicate that pH 6.8 Offers Best Stability Profile




# Low Temperature Region Provides Clues to Long Term Stability. Kinetic Deconvolution Allows Extrapolation of Cp Components




Cp2 and Cp3 are the first to start denaturation. Even though they have higher Tm's they have lower  $\Delta H^*$

# At Low Temperatures Cp3 is the Least Stable Domain. pH 6.8 Appears to be the Most Appropriate pH



# Further Formulation Optimization at pH 6.8. Addition of Excipients: DSC of VRC07 in Buffers 1 - 4





Buffer 1 - 50mM Histidine, 100mM NaCl, pH 6.8

Buffer 2 - 50mM Histidine, 100mM NaCl, 5% w/v sucrose, pH 6.8

Buffer 3 - 50mM Histidine, 100mM NaCl, 5% w/v sorbitol, pH 6.8



Buffer 4 - 50mM Histidine, 50mM NaCl, 5% w/v sucrose, 2.5% w/v sorbitol, pH 6.8

# Effect of Excipients in $T_m$ 's and $\Delta H^*$ 's of VRC07 at pH 6.8



$T_m$ 's show an increase for all transitions. Activation enthalpy is fairly constant for transitions 1 and 3. Buffer 4 is the best overall.


# Improvement of Low Temperature Stability by Excipients



Sum  
Cp1  
Cp2  
Cp3


Notice that Formulation Optimization is a Combination of  $T_m$  and Activation Enthalpy

# Isothermal Calorimetry



Denaturation and Aggregation Involve the Absorption or Release of Heat and Therefore Can Be Measured Calorimetrically at Constant Temperature

# TAM Isothermal Calorimeter




# VP DSC. Little Known Isothermal Mode




## Isothermal Operation

The VP-DSC has two basic modes of operation; scanning (Conventional DSC) and isothermal (Isothermal Scan Mode). Scanning mode uses a linearly increasing or decreasing temperature ramp function, while measuring the differential power between the reference and sample cells. This mode is referred to as 'Conventional DSC' from within VPViewer.

A second mode of operation is also available, namely Isothermal mode. In Isothermal mode, a constant temperature is maintained for relatively long periods of time while measuring differential power between the reference and sample cells. Isothermal mode is commonly used in evaluating the stability of drug formulations, as in shelf life studies. To carry out an Isothermal mode scan (IsoScan), the user must first select the Isothermal mode of operation from within the Experimental Control window. From the Experimental Control window, select the menu Cell 1|DSC Scan Mode|Isothermal Scan Mode, as shown below.



# Isothermal Calorimetry




$$Q = \frac{\text{Heat}}{v[P_T]} = \Delta H_u F_u + Q_{agg} F_u F_{agg}$$

$$Q = \Delta H_u (1 - e^{-k_u t}) + Q_{agg} (1 - e^{-k_u t}) (1 - e^{-k_{agg} t})$$


Quantity Measured by Calorimeter is Heat Flow:  $dQ/dt$

$$dQ/dt = k_u \Delta H_u e^{-k_u t} + k_{agg} Q_{agg} e^{-k_{agg} t} + k_u Q_{agg} e^{-k_u t} - (k_u + k_{agg}) Q_{agg} e^{-(k_u + k_{agg}) t}$$



# Two Different Situations for Protein Denaturation/Aggregation




Denaturation Precedes Aggregation




Denaturation, Aggregation Occur Simultaneously




# Temperature Denaturation and Aggregation of mAb VRC07




DSC of VRC07




Isothermal Calorimetry at 60°C, 100 mg/mL




# Denaturation/Aggregation Measured by Isothermal Calorimetry (100mg/mL)



# Kinetics of Denaturation/Aggregation Buffers 1 and 4 at 60°C (Isothermal Calorimetry Data)




# VRC07 Denaturation/Aggregation Rates in Different Formulations at 60°C




Discrimination Between Different Formulations

# SEC chromatograms of VRC07 in the four formulation buffers after 12 weeks storage at 25°C:




red: buffer 1  
blue: buffer 2  
green: buffer 3  
black: buffer 4

# SEC Data for Four Different Formulations at 25°C



# Correlation Between SEC and Isothermal Calorimetry Rates



# Conclusions

- Kinetic Deconvolution of DSC: Activation enthalpies for each denaturation peak. Temperature dependence of denaturation rates. Combined analysis of  $\Delta H^*$  and  $T_m$  allows selection of best formulation.
- Isothermal Calorimetry: Rates of denaturation/aggregation at constant temperature can be determined in one week. Correlates well with SEC data and can be used to assess quality of antibody or formulation.

For additional information or to discuss a collaboration please contact E. Freire at [ef@jhu.edu](mailto:ef@jhu.edu)